Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-05-31

Clinical Trial Update: A Study of Paliperidone Palmitate 6-Month Formulation [Phase 3]

View source ↗

Summary

Phase 3 study evaluating paliperidone palmitate for schizophrenia has completed and posted results for the 6-month formulation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Paliperidone palmitate 6-month formulation (paliperidone palmitate)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED | Results posted: 2023-05-31